mHSPC和nmCRPC的临床、诊断和治疗框架：意大利泌尿肿瘤学会（SIUrO）的多学科共识项目。

IF 2.3 3区医学 Q3 ONCOLOGY

Clinical genitourinary cancer Pub Date : 2025-02-01 DOI:10.1016/j.clgc.2024.102292

Rolando Maria D'Angelillo , Orazio Caffo , Nicolò Borsellino , Giampiero Cardone , Giuseppe Ferdinando Colloca , Giario Natale Conti , Marzia Del Re , Stefano Fanti , Barbara Alicja Jereczek-Fossa , Alberto Lapini , Giovanni Luigi Pappagallo , Tommaso Prayer Galetti , Sergio Bracarda

{"title":"mHSPC和nmCRPC的临床、诊断和治疗框架：意大利泌尿肿瘤学会（SIUrO）的多学科共识项目。","authors":"Rolando Maria D'Angelillo , Orazio Caffo , Nicolò Borsellino , Giampiero Cardone , Giuseppe Ferdinando Colloca , Giario Natale Conti , Marzia Del Re , Stefano Fanti , Barbara Alicja Jereczek-Fossa , Alberto Lapini , Giovanni Luigi Pappagallo , Tommaso Prayer Galetti , Sergio Bracarda","doi":"10.1016/j.clgc.2024.102292","DOIUrl":null,"url":null,"abstract":"<div><div>The recent evidences provided in metastatic hormone sensitive prostate cancer (nmHSPC) and in nonmetastatic castration resistant (nmCRPC) introduced the possibility to adopt Androgen Receptor Signaling inhibitor (ARSi) alone (both settings) or with chemotherapy (in mHSPC). In daily clinical practice there are some opening questions regarding the inclusion of next generation imaging, mainly PSMA-PET, how integrate local treatment as radiotherapy, how to select patients or drugs in a multiple-choice scenario, and how to manage patients with comorbidities and polypharmacy. These issues led the Italian Society for Uro-Oncology (SIUrO) to develop a consensus project involving all of the most important Italian scientific societies engaged in the multidisciplinary and multiprofessional management of the disease. This paper describes the items and statements approved, with the aim to support clinicians in managing metastatic hormone sensitive and nonmetastatic castration resistant prostate cancer patients.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 1","pages":"Article 102292"},"PeriodicalIF":2.3000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical, Diagnostic and Therapeutic Framework of mHSPC and nmCRPC: A Multidisciplinary Consensus Project of the Italian Society for Uro-Oncology (SIUrO)\",\"authors\":\"Rolando Maria D'Angelillo , Orazio Caffo , Nicolò Borsellino , Giampiero Cardone , Giuseppe Ferdinando Colloca , Giario Natale Conti , Marzia Del Re , Stefano Fanti , Barbara Alicja Jereczek-Fossa , Alberto Lapini , Giovanni Luigi Pappagallo , Tommaso Prayer Galetti , Sergio Bracarda\",\"doi\":\"10.1016/j.clgc.2024.102292\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The recent evidences provided in metastatic hormone sensitive prostate cancer (nmHSPC) and in nonmetastatic castration resistant (nmCRPC) introduced the possibility to adopt Androgen Receptor Signaling inhibitor (ARSi) alone (both settings) or with chemotherapy (in mHSPC). In daily clinical practice there are some opening questions regarding the inclusion of next generation imaging, mainly PSMA-PET, how integrate local treatment as radiotherapy, how to select patients or drugs in a multiple-choice scenario, and how to manage patients with comorbidities and polypharmacy. These issues led the Italian Society for Uro-Oncology (SIUrO) to develop a consensus project involving all of the most important Italian scientific societies engaged in the multidisciplinary and multiprofessional management of the disease. This paper describes the items and statements approved, with the aim to support clinicians in managing metastatic hormone sensitive and nonmetastatic castration resistant prostate cancer patients.</div></div>\",\"PeriodicalId\":10380,\"journal\":{\"name\":\"Clinical genitourinary cancer\",\"volume\":\"23 1\",\"pages\":\"Article 102292\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical genitourinary cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1558767324002623\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767324002623","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

最近在转移性激素敏感前列腺癌（nmHSPC）和非转移性去势抵抗（nmCRPC）中提供的证据介绍了单独使用雄激素受体信号抑制剂（ARSi）（两种情况）或联合化疗（mHSPC）的可能性。在日常临床实践中，关于下一代影像学（主要是PSMA-PET）的纳入，如何将局部治疗与放疗相结合，如何在多项选择方案中选择患者或药物，以及如何管理合并合并症和多重用药的患者，存在一些悬而未决的问题。这些问题促使意大利泌尿肿瘤学会（SIUrO）制定了一个共识项目，涉及从事该疾病多学科和多专业管理的所有最重要的意大利科学学会。本文描述了批准的项目和声明，旨在支持临床医生管理转移激素敏感和非转移性去势抵抗前列腺癌患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Clinical, Diagnostic and Therapeutic Framework of mHSPC and nmCRPC: A Multidisciplinary Consensus Project of the Italian Society for Uro-Oncology (SIUrO)

The recent evidences provided in metastatic hormone sensitive prostate cancer (nmHSPC) and in nonmetastatic castration resistant (nmCRPC) introduced the possibility to adopt Androgen Receptor Signaling inhibitor (ARSi) alone (both settings) or with chemotherapy (in mHSPC). In daily clinical practice there are some opening questions regarding the inclusion of next generation imaging, mainly PSMA-PET, how integrate local treatment as radiotherapy, how to select patients or drugs in a multiple-choice scenario, and how to manage patients with comorbidities and polypharmacy. These issues led the Italian Society for Uro-Oncology (SIUrO) to develop a consensus project involving all of the most important Italian scientific societies engaged in the multidisciplinary and multiprofessional management of the disease. This paper describes the items and statements approved, with the aim to support clinicians in managing metastatic hormone sensitive and nonmetastatic castration resistant prostate cancer patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical genitourinary cancer 医学-泌尿学与肾脏学

CiteScore

5.20

自引率

6.20%

发文量

201

审稿时长

54 days

期刊介绍： Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.